Browsing Tag
Foster City
3 posts
How a first-in-class HDV approval could support Gilead Sciences’ long-term antiviral portfolio
Find out how Hepcludex approval could strengthen Gilead Sciences’ antiviral portfolio and reshape HDV care in the U.S.
Why GILD stock sentiment may depend on more than one positive Phase 3 liver disease result
Find out why GILD stock sentiment may need more than positive Livdelzi data as investors weigh Gilead’s liver disease growth strategy.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.